zealand pharma petrelintide - Search News

Zealand Pharma to pay $350M to Roche

The Wall Street Journal on MSN · 3d

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.

Seeking Alpha on MSN · 3d

Roche, Zealand Pharma enter $5.3B license deal for obesity treatment

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF). Under the terms of deal,

Markets Insider · 3d

Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a

3d

Roche And Zealand Team Up To Develop Petrelintide

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

3don MSN

Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

Fierce Biotech3d

Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

3don MSN

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results